NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Nov 9, 2020--

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced that management will present at two investor conferences in November.

  • Credit Suisse 29th Annual Virtual Healthcare Conference
    • Date: Wednesday, November 11, 2020
    • Time: 9:30am Eastern Time
    • Participants: Mary Anne Heino, President and Chief Executive Officer and Bob Marshall, Chief Financial Officer and Treasurer
  • Jefferies Virtual London Healthcare Conference
    • Date: Tuesday, November 17, 2020
    • Time: 7:20am Eastern Time
    • Participant: Bob Marshall, Chief Financial Officer and Treasurer

To access a live webcast of the presentation, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcast will be available on the Company’s website for 30 days following the live presentation.

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB, and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite ® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; AZEDRA ® for the treatment of certain rare neuroendocrine tumors; and RELISTOR ® for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies, Inc. The Company is headquartered in North Billerica, Massachusetts with offices in New York, New Jersey, Puerto Rico, Canada and Sweden. For more information, visit www.lantheus.com.

CONTACT: Mark Kinarney

Senior Director, Investor Relations

978-671-8842

ir@lantheus.com Melissa Downs

Director, Corporate Communications

646-975-2533

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY

SOURCE: Lantheus Holdings, Inc.

Copyright Business Wire 2020.

PUB: 11/09/2020 04:30 PM/DISC: 11/09/2020 04:31 PM

Copyright Business Wire 2020.